Matthew Angel - 01 Aug 2022 Form 4 Insider Report for Brooklyn ImmunoTherapeutics, Inc. (ERNA)

Role
Interim President and CEO, Director
Signature
/s/ Matthew Angel
Issuer symbol
ERNA
Transactions as of
01 Aug 2022
Transactions value $
$0
Form type
4
Filing time
03 Aug 2022, 20:01:34 UTC
Previous filing
01 Jun 2022
Next filing
13 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ERNA Stock Option (right to buy) Award $0 +2.49M $0.00 2.49M 01 Aug 2022 Common Stock, par value $0.005 per share 2.49M $0.49 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable over four years (subject to continued service), with 2/48th of the shares vesting on the grant date and the remaining shares vesting in 46 substantially equal monthly installments thereafter.